Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2415
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration ; volume:20 ; number:1 ; day:10 ; month:7 ; year:2020 ; pages:1-7 ; date:12.2020
BMC ophthalmology ; 20, Heft 1 (10.7.2020), 1-7, 12.2020
- Urheber
-
Itagaki, Kanako
Sekiryu, Tetsuju
Kasai, Akihito
Sugano, Yukinori
Ogasawara, Masashi
Saito, Masaaki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12886-020-01542-6
- URN
-
urn:nbn:de:101:1-2020090820090960196494
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Itagaki, Kanako
- Sekiryu, Tetsuju
- Kasai, Akihito
- Sugano, Yukinori
- Ogasawara, Masashi
- Saito, Masaaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis